This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Omeprazole Delayed Release (DR) Capsules Bioequivalence Study of Dr. Reddys Under Fed Condition

This study has been completed.
Information provided by:
Dr. Reddy's Laboratories Limited Identifier:
First received: May 31, 2010
Last updated: July 26, 2010
Last verified: May 2010
This study examines the bioequivalence of Dr. Reddy's Omeprazole delayed release capsules under fed condition.

Condition Intervention Phase
Healthy Drug: Omeprazole Device: Prilosec® 40 mg Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study to Compare Omeprazole 40 mg DR Capsules Dr. Reddy's Laboratories Ltd.,With Prilosec® 40 mg Merck & Co., Inc.,USA Under Fed Condition

Resource links provided by NLM:

Further study details as provided by Dr. Reddy's Laboratories Limited:

Primary Outcome Measures:
  • Bioequivalence based on Cmax and AUC parameters [ Time Frame: 4 months ]

Enrollment: 54
Study Start Date: February 2006
Study Completion Date: April 2006
Primary Completion Date: April 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Omeprazole
Omeprazole Delayed Release Capsules of Dr. Reddy's Laboratories Limited
Drug: Omeprazole
Omeprazole Delayed Release Capsules 40 mg
Other Name: Prelosec 40 mg
Active Comparator: Prilosec
Prilosec® 40 mg Merck & Co. Inc
Device: Prilosec® 40 mg
Prilosec® 40 mg
Other Name: Omeprazole

Detailed Description:
This is a randomized, two-treatment, two-period, two-sequence, single dose, crossover bioequivalence study to compare Omeprazole 40 mg Delayed Release Capsules (Dr. Reddy's Laboratories Ltd.,) with Prilosec® 40 mg (Omeprazole Delayed Release Capsules) (manufactured by Merck & Co., Inc., USA) in 54 healthy, adult, human subjects under fed conditions.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects who provided written informed consent.
  • Subjects who were healthy within 18-45 years of age, weighing at least 50 kg.
  • Body mass index of ≥18 kglm2 and ≤ 25 kg/m2, with body weight not less than 50 kg.
  • Subjects with normal health as determined by medical history and physical examination performed within 15 days prior to the commencement of the study (dosing in period-I).
  • Subjects with normal ECG, chest X-ray (PA view) and vital signs.
  • Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by written informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01170182

Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Principal Investigator: Manoj K Bose, Dr. Vimta Labs Limited, 142, IDA, Phase-II, Cherlapally, Hyderabad, India-500 051
  More Information

Responsible Party: Assistant Manager - Research & Development, Dr. Reddy's Laboratories Limited, Identifier: NCT01170182     History of Changes
Other Study ID Numbers: 7577/05-06
Study First Received: May 31, 2010
Last Updated: July 26, 2010

Additional relevant MeSH terms:
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017